Samsung Bioepis Presents Two Abstracts for Its Immunology Po

Interchangeability study for HADLIMA (adalimumab-bwwd) was conducted in accordance with the FDA’s Guidance for Industry; primary pharmacokinetics (PK) endpoints as well as efficacy, safety and immunogenicity profiles were comparable between switching group and continuous reference product Humira group 52-week results from SB17 Phase 3 study demonstrated long-term efficacy, safety, and immunogenicity of SB17 compared to reference ustekinumab, including switching from ustekinumab to SB17 INCHEON,

Related Keywords

United States , California , San Diego , American , Skaidra Valiukevi , Maria Agnieszka Zegadlo Mylik , Lidia Rajzer , Ilsun Hong , Jan Brzezicki , Malgorzata Janczylo Jankowska , Anna Nayun Kim , Minkyung Lee , Magdalena Dmowska Stecewicz , Stevenr Feldman , Joanna Narbutt , Hyuna Lee , Elzbieta Krolikowska , Nataliya Reznichenko , Samsung Bioepi , Jiyoon Lee , Hidradenitis Suppurativa , Yumin Baek , Young Hee Rho , Soyeon Kim , Bartlomiej Kwiek , Samsung Bioepis , Giampiero Girolomoni , Pawel Brzewski , Jane Chung , Drug Administration , Production Evaluation Team Leader Of Samsung Bioepis , American Academy Of Dermatology , Johnson , Linkedin , Committee For Medicinal Products Human Use , European Medicines Agency , Samsung Bioepis Co Ltd , Abbvie Biotechnology Ltd , Annual Meeting , Vice President , Production Evaluation Team Leader , Medicinal Products , Human Use , Biologics License Application , Adalimumab Reference Product , Severe Chronic Plaque , Grazyna Pulka , Proposed Ustekinumab Biosimilar , Reference Ustekinumab , Isevere Plaque Psoriasis , Myoung Hee , Idiopathic Arthritis , Full Prescribing Information , Boxed Warning , Medication Guide , Abbvie Biotechnology , Nayun Kim ,